Leva
Latest round
- Series A
Last raised
- Oct 2022
Total raised
- $2.1M
Investors
- 2
About Leva
, trading as Leva, is a platform for pain management that offers an online clinic for treating chronic pain with medical professionals. As of 2022, Eric Bystrom is the CEO of the company. The company provides a digital chronic pain platform that offers treatment for conditions including back pain, neck pain, knee pain, pelvic pain, sciatica, arthritis, multiple sclerosis, fibromyalgia pain, and cancer pain. The firm's partners include Imperial College London, Boots, the NHS, and Connect Health. The startup generates revenue through its treatment plans, such as the online clinic plan for GBP 99 for the initial consultation and the pain management programme for GBP 60 as a one-time payment.
Who invested in Leva
2 investors across 1 round
See all investors in Leva
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Oct 28, 2022
Amount
$2.1M
Investors
Questions about Leva
Who invested in Leva?
Leva has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Leva raised?
Leva has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Leva last raise money?
Leva's most recent round on record is a Series A, in Oct 2022.
What does Leva do?
, trading as Leva, is a platform for pain management that offers an online clinic for treating chronic pain with medical professionals.
Where is Leva headquartered?
Leva is headquartered in London, UK.
Which VCs invest in companies like Leva?
Among active investors with capital left to deploy, Index Ventures, Forbion, Balderton Capital and Sofinnova Partners back healthcare companies at Leva's stage. Their profiles are linked below.
VCs backing healthcare startups at Series A
Raising like Leva? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.